Clinical ethics in oncology [0.03%]
肿瘤学临床伦理学
Sergio Huerta
Sergio Huerta
Tertiary lymphoid structure transcriptomic signatures show limited and cohort-dependent value for predicting axillary nodal involvement in oestrogen receptor-positive luminal breast cancer [0.03%]
三级淋巴器官结构转录特征在预测雌激素受体阳性乳状乳腺癌腋窝淋巴结转移中的价值有限且依赖队列
Tao Wang,Yi Zhang,Xinhua Yang et al.
Tao Wang et al.
Tertiary lymphoid structures (TLS) are associated with prognosis in solid tumours. Their value for predicting axillary nodal involvement in oestrogen receptor-positive luminal breast cancer remains uncertain. Three published TLS signatures ...
Akt inhibitor-IV in estrogen receptor-positive breast cancer cells: cytotoxic, apoptotic, transcriptional, and in-silico comparison with tamoxifen [0.03%]
Akt抑制剂-IV与他莫昔芬对雌激素受体阳性乳腺癌细胞的作用机制比较研究
Ahmet Karakuş,Orhan Erdoğan
Ahmet Karakuş
Dysregulation of the phosphoinositide 3-kinase/protein kinase B (AKT)/mechanistic target of rapamycin pathway is a hallmark of breast cancer, making AKT a focus of therapeutic interest. AKT inhibitor-IV is a benzimidazolium compound that in...
Prolonged multimodal disease control with trifluridine/tipiracil plus bevacizumab in KRAS-mutant metastatic rectal cancer: a case report [0.03%]
三氟尿苷/-tipiracil联合贝伐珠单抗治疗KRAS突变型转移性直肠癌的多模式疾病控制：一例报告
Onur Alkan,Ahmet Başgöze,İsmail Nazli
Onur Alkan
Refractory metastatic colorectal cancer (mCRC) management is further complicated when fluoropyrimidine-based therapy is contraindicated, leaving few systemic options. We present a 57-year-old man with KRAS G13D-mutant, liver-dominant metast...
Growth differentiation factor-11 inhibits the progression of acute myeloid leukemia and increases chemosensitivity by inhibiting cathepsin S [0.03%]
生长分化因子-11通过抑制猫屎蛋白S抑制急性髓系白血病的发展并提高化学敏感性
Jie Luo,Yun Xu,Lina Zhang et al.
Jie Luo et al.
Growth differentiation factor-11 (GDF11) is an important member of the transforming growth factor-β superfamily and plays an important role in tumor progression. However, its role and prognostic value in acute myeloid leukemia (AML) have n...
Inavolisib and lenvatinib for PIK3CA-mutated refractory splenic angiosarcoma: a case report [0.03%]
伊纳福马利布联合仑伐替尼治疗PIK3CA突变难治性脾血管肉瘤1例报告
Xinyue Zhao,Chenyu Wang,Yuping Ge et al.
Xinyue Zhao et al.
Primary splenic angiosarcoma (PSA) is a rare vascular malignancy with a poor prognosis and limited therapeutic options. A 62-year-old man with metastatic PSA underwent splenectomy followed by first-line paclitaxel, achieving stable disease ...
Drug repurposing of liver cancer based on multimodal neural network and virtual screening [0.03%]
基于多模态神经网络和虚拟筛选的肝癌老药新用研究
Xu Huang,Xiaoqian Jia,Yu Zhou et al.
Xu Huang et al.
Liver cancer is a malignant tumor with high incidence and mortality rates globally. Existing therapeutic methods have certain limitations in terms of efficacy, safety, and applicability, creating an urgent need for the development of new tr...
Discovery of an orally active and liver-targeted dual prodrug of 5-fluoro-2'-deoxyuridine-5'-monophosphate for the treatment of hepatocellular carcinoma [0.03%]
一种口服活性的、针对肝脏的5-氟-2'-脱氧尿苷-5'-磷酸普 Drugs治疗肝细胞癌双前药的研究发现
Ming Yang,Xing-Long Dai,Cheng-Wei He et al.
Ming Yang et al.
Hepatocellular carcinoma (HCC) is a leading cause of cancer-related deaths globally. Hepatic arterial infusion chemotherapy with 5-fluorouracil (5-FU) have been considered; however, it has limited survival benefits because of unbearable tox...
The novel integrin-linked kinase inhibitor nilotinib suppresses cancer progression by promoting ubiquitylation of autoimmune regulator in oesophageal squamous cell carcinoma [0.03%]
一种新的整合素连接激酶抑制剂尼洛替尼通过促进自身免疫调节蛋白泛素化来抑制食管鳞癌的进展
Xiaoli Ma,Yu Wei,LeiYu Cao et al.
Xiaoli Ma et al.
Integrin-linked kinase (ILK) is a key oncogenic driver in oesophageal squamous cell carcinoma (ESCC). This study evaluated the antitumour effects of the novel ILK inhibitor Nilotinib and explored its downstream mechanisms. In vitro, TE-1 an...